Trans No.	Acquiring	Acquired	Entities
20061845	Tenaska Power Fund, L.P	William J. Haugland	Bemis, LLC., Halpin Line Construction, LLC., Hawkeye Group, LLC. Premier Utility Locating, LLC.
20061848	Corel Holdings, L.P	InterVideo, Inc	InterVideo, Inc.
20061857	Wind Point Partners VI, L.P	Spire Capital Partners, L.P	Highline Data, LLC., The National Underwriter Company.
20061858	Citizens Communications Company	Commonwealth Telephone Enterprises, Inc.	Commonwealth Telephone Enterprises, Inc.
20061863	Edmund N. Ansin	Tribune Company	WLVI, Inc.
20061870	Illinois Tool Works, Inc	Click Commerce, Inc	Click Commerce, Inc.
20061872	Canadian Natural Resources, Limited	Anadarko Petroleum Corporation	Anadarko Canada Corporation.
20070003	Hospitality Properties Trust	Oak Hill Capital Partners, L.P	TravelCenters of America, Inc.
Transactions Granted Early Termination—10/11/2006			
20061810	AT&T, Inc	Interpath Communications, Inc	Interpath Communications, Inc.
20061849	John C. Hampton Revocable Trust	West Fraser Timber Co., Ltd	Babine Forest Products, Limited.
20061869	Issac E. Larian and Angela Larian	Newell Rubbermaid Inc	The Little Tikes Company, Inc.
20061871	BB&T Corporation	Mellon Financial Corporation	AFCO Credit Corporation.
Transactions Granted Early Termination—10/13/2006			
20061803	Medical Action Industries, Inc	Medegen Holdings, LLC	Medegen Newco, LLC.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay, Contact Representative, or Renee Hallman, Contact Representative, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H–303, Washington, DC 20580, (202) 326–3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 06–8901 Filed 10–25–06; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

[Document Identifier: OS–0990–000]

30-Day Notice; Agency Information Collection Activities: Proposed Collection; Comment Request

Agency: Office of the Secretary.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Regular, New Collection.

Title of Information Collection: The Effect of Reducing Falls on Acute and Long-Term Care Expenses.

Form/OMB No.: OS–0990–New.

Attention: ASPE is planning to conduct a demonstration and evaluation of a multi-factorial fall prevention program to measure its impact on health outcomes for the elderly as well as acute and long-term care use and cost. This will be accomplished by obtaining a sample of individuals with private long-term care insurance who are age 75 and over.

Frequency: One Time On Occasion.

Affected Public: Individual or Households.

Annual Number of Respondents: 9720.

Total Annual Responses: 9,600.

Average Burden Per Response: 3.54 min.

Total Annual Hours: 4305.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, e-mail your request, including your address, phone number, OMB number, and OS document identifier, to Sherette.funncoleman@hhs.gov, or call the Reports Clearance Office on (202) 690–6162. Written comments and recommendations for the proposed information collections must be received within 30 days of this notice directly to the

Desk Officer at the address below:

OMB Desk Officer: John Kraemer, OMB Human Resources and Housing Branch, Attention: (OMB #0990–New), New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: October 23, 2006.

Alice Bettencourt,

Office of the Secretary, Paperwork Reduction Act Reports Clearance Officer.

[FR Doc. E6–17943 Filed 10–25–06; 8:45 am]

BILLING CODE 4151–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N–0535]

Agency Information Collection Activities; Announcement of Office of Management and Budget; Extension of Expiration Date for MedWatch (Food and Drug Administration Medical Products Reporting Program) Form

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of expiration date.

SUMMARY: The Food and Drug Administration (FDA) is announcing that, under the Paperwork Reduction Act of 1995 (the PRA), the Office of Management and Budget (OMB) has extended the expiration date to May 1, 2007, for the use of the prior version of Form FDA 3500A for ''MedWatch: Food and Drug Administration Medical

Products Reporting Program'' (the MedWatch Program).

FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 16, 2005 (70 FR 48157), FDA announced that a proposed collection of information entitled ''MedWatch: Food and Drug Administration Medical Products Reporting Program'' had been submitted to OMB for approval under the PRA. The collection of information included the use of two forms used in the MedWatch Program—Form FDA 3500 and Form FDA 3500A. In that notice, we responded to public comments pertaining to proposed revisions to Form FDA 3500 and Form FDA 3500A. Several comments from industry stated that considerable resources would be required to modify computer systems and processes to begin using the mandatory reporting form—Form FDA 3500A. In response to these comments, we stated: ''[T]o allow mandatory reporters time to make the necessary changes to their computer systems and processes to conform to the revised Form FDA 3500A, FDA is granting a grace period of 1 year. During this transition period FDA will accept both the newly effective Form FDA 3500A and the prior version of the form.''

In the **Federal Register** of December 7, 2005 (70 FR 72843), FDA announced that OMB had approved the information collection for the MedWatch Program as submitted to OMB on August 16, 2005. In that notice, we stated: ''As requested by the agency, in addition to the approval of the revised forms, the existing forms are approved for continued use for the next 12 months to allow for the industry to make necessary changes to their computerized systems.'' In response to several recent requests from industry that we grant more time to make necessary changes to computerized systems, we requested and OMB has agreed to extend approval to use the prior version of Form FDA 3500A until May 1, 2007. The expiration date for the newly revised Form FDA 3500A remains unchanged—October 31, 2008. The prior version of Form FDA 3500A is available for downloading at *http://www.fda.gov/medwatch/getforms.htm*, and the expiration date on the form has been revised to May 1, 2007.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Dated: October 19, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E6–17907 Filed 10–25–06; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Dental Products Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Dental Products Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 9, 2006, from 8 a.m. to 5 p.m.

Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Michael J. Ryan, Center for Devices and Radiological Health (HFZ–480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–827–5283, ext. 175, e-mail at: *michael.ryan@fda.hhs.gov*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512518. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss, make recommendations, and vote on a premarket approval application for a collagen material, which contains a bone morphogenetic protein, for oral maxillofacial bone grafting procedures. Background information, including the agenda and questions for the committee, will be available to the public 1 business day before the meeting on the Internet at *http://www.fda.gov/cdrh/panel* (click on Upcoming CDRH Advisory Panel/Committee Meetings).

Procedure: On November 9, 2006, from 8:30 a.m. to 5 p.m., the meeting will be open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 2, 2006. Oral presentations from the public will be scheduled for approximately 30 minutes at the beginning of committee deliberations and for approximately 30 minutes near the end of the deliberations. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 2, 2006.

Closed Committee Deliberations: On November 9, 2006, from 8 a.m. to 8:30 a.m., the meeting will be closed to the public to permit FDA to present to the committee trade secret and/or confidential commercial information regarding pending and future agency issues (5 U.S.C. 552b(c)(4)) for the next year.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams, Conference Management Staff, 301–827–7291, at least 7 days in advance of the meeting.

FDA regrets that it was unable to publish this notice 15 days prior to the Dental Products Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Dental Products Panel of the Medical Devices Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).